首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin
【24h】

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

机译:HMG-CoA还原酶抑制剂对单芥子碱诱导的大鼠肺动脉高压的保护作用可能不是类别的作用:普伐他汀和阿托伐他汀的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline (MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin (PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine- or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase (eNOS) expression. MC-rat lungs showed a significant decrease of eNOS (P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension (RVP in mmHg: 30 ± 3, 36 ± 4 vs. 45 ± 4 and 14 ± 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 ± 0.04, 0.39 ± 0.03, 0.62 ± 0.05 and 0.29 ± 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05),and reduced MC-induced thickening (61 ± 6 μm, 82 ± 5 μm, 154 ± 4 μm, and 59 ± 2 μm for MC + PS, MC + AS, MC, and control groups, respectively; P = 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (Emax=65 ± 5%, 49 ± 6%, 46 ± 3%, and 76 ± 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.
机译:羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,称为他汀类药物,可改善内皮功能,并对全身血管的平滑肌细胞发挥抗增殖作用。这项研究旨在比较普伐他汀和阿托伐他汀这两种他汀类药物对单芥子碱(MC)诱导的大鼠肺动脉高压的保护作用。口服或不注射MC(腹腔注射60 mg / kg)的Wistar雄性大鼠口服普伐他汀或阿托伐他汀(PS或AS,每天10 mg / kg)或赋形剂28天。在第4周,注射MC的大鼠发展为严重的肺动脉高压,右心室压力(RVP)和右心室/左心室+隔垫重量比增加,并伴有乙酰胆碱或亚硝普钠诱导的肺动脉扩张减少体外。高血压肺动脉的中层厚度和内皮细胞凋亡增加,内皮一氧化氮合酶(eNOS)表达降低。通过Western印迹测定,MC鼠肺显示eNOS显着降低(P <0.01),裂解的caspase-3表达增加(P <0.05)。 PS(P = 0.02)但非AS(P = 0.30)显着限制了肺动脉高压的发展(mmHg的RVP:MC + PS,MC + AS为30±3、36±4与45±4和14±1 ,MC和对照组)。两种他汀类药物均可显着降低MC诱发的右心室肥大[RV /左心室(LV)+ S,单位mg / g:MC + PS,MC + AS,0.46±0.04、0.39±0.03、0.62±0.05和0.29±0.01, MC和对照组; P <0.05),并降低了MC引起的增厚(对于MC + PS,MC + AS,MC和对照组,分别为61±6μm,82±5μm,154±4μm和59±2μm; P = 0.01)小肺内动脉内壁,MC + AS仍与对照组不同。 PS而不是AS可以部分恢复MC大鼠的乙酰胆碱诱导的肺动脉血管舒张(MC + PS,MC + AS的Emax = 65±5%,49±6%,46±3%和76±4% ,MC和对照组; MC + PS与其他组相比,P <0.05)。两种他汀类药物均能预防肺动脉内皮细胞以及整个肺的凋亡并恢复eNOS表达,与AS相比,PS的作用更为明显。总之,尽管它对eNOS的表达,细胞凋亡和内壁增厚有影响,但AS不能显着降低肺动脉高压并不能恢复内皮依赖性舒张功能,这表明两种HMG-CoA还原酶抑制剂在分子保护方面对MC-诱发高血压。

著录项

  • 来源
    《Naunyn-Schmiedeberg's Archives of Pharmacology》 |2006年第3期|195-206|共12页
  • 作者单位

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of Burgundy;

    Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979) University of BurgundyLPPCE Faculté de Médecine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Reductase inhibitors; Pravastatin; Atorvastatin; Pulmonary arterial hypertension;

    机译:还原酶抑制剂;普伐他汀;阿托伐他汀;肺动脉高压;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号